TFE3-Splicing Factor Fusions Represent Functional Drivers and Druggable Targets in Translocation Renal Cell Carcinoma

Nur P. Damayanti(University of Indianapolis), Roberto Pili(Indiana University Health)

Cancer Research

January 24, 2024

10.1158/0008-5472.can-23-1789

Cited by 9

Related Papers

Therapeutic Targeting of TFE3/IRS-1/PI3K/mTOR Axis in Translocation Renal Cell Carcinoma

|Clinical Cancer Research|2018|95

EZH2 Modifies Sunitinib Resistance in Renal Cell Carcinoma by Kinome Reprogramming

|Cancer Research|2017|74

Immunomodulation by HDAC inhibition: Results from a phase Ib study with vorinostat and pembrolizumab in metastatic urothelial, renal, and prostate carcinoma patients.

|Journal of Clinical Oncology|2019|21

Integrative Multi-OMICs Identifies Therapeutic Response Biomarkers and Confirms Fidelity of Clinically Annotated, Serially Passaged Patient-Derived Xenografts Established from Primary and Metastatic Pediatric and AYA Solid Tumors

|Cancers|2022|14

Abstract 2366: HDAC inhibition improves immune checkpoint inhibitor efficacy in renal cell carcinoma

|Cancer Research|2019|1